Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial

Xin Sun, Anzhong Zhang, Tao Zhou, Minghui Wang, Yong Chen, Ting Zhou, Xiaoning Chen, Aiyuan Xiu, Zhi Peng, Baoquan Cheng, Xiaofeng Liu, Yanjing Gao, Xin Sun, Anzhong Zhang, Tao Zhou, Minghui Wang, Yong Chen, Ting Zhou, Xiaoning Chen, Aiyuan Xiu, Zhi Peng, Baoquan Cheng, Xiaofeng Liu, Yanjing Gao

Abstract

Background: Global research on endoscopic therapies in combination with partial splenic embolization (PSE) for variceal hemorrhage (VH) is limited. Therefore, we aimed to evaluate the efficacy and safety of endoscopy plus PSE (EP) treatment in comparison to endoscopic (E) treatment for the secondary prophylaxis of VH in cirrhosis patients with hypersplenism.

Methods: Cirrhosis patients with hypersplenism (platelet count < 100, 000/µL) and those who had recovered from an episode of VH were enrolled in a multicenter randomized controlled trial. The participants were randomly assigned into EP and E groups in a 1:1 ratio. The primary endpoint was variceal rebleeding, and the secondary endpoints were severe variceal recurrence and mortality during the 2-year follow-up. Hematological indices, serum biochemical parameters, and the Child-Pugh score were measured at each time point.

Results: From June 2016 to December 2019, 108 patients were enrolled in the study, among which 102 patients completed the protocol (51 in EP and 51 in E group). The rebleeding rate of the varices was significantly reduced in the EP group compared to that in the E group during the 2 years (16% vs. 31%, p < 0.001). The EP group showed a significantly lower variceal recurrence rate than the E group (22% vs. 67%, p < 0.001). The COX proportional hazard models revealed that grouping was an independent predictor for variceal rebleeding (H = 0.122, 95% CI 0.055-0.270, p < 0.001) and variceal recurrence (hazard ratio, H = 0.160, 95% CI 0.077-0.332, p < 0.001). The peripheral blood cell count, Child-Pugh class/score, albumin concentration, and coagulation function in the EP group improved significantly compared to the values observed in the E group at any time point (p < 0.05).

Conclusions: The EP treatment was more effective in preventing variceal rebleeding and variceal recurrence than the conventional E treatment during the secondary prophylaxis of VH in cirrhosis patients with hypersplenism. Furthermore, the EP treatment could significantly increase the peripheral blood cell count and albumin concentration and also improved the coagulation function and the Child-Pugh score.

Clinical trials registration: Trial registration number ClincialTrials.gov: NCT02778425. The URL of the clinical trial: https://clinicaltrials.gov/.

Keywords: Cyanoacrylate injection; Endoscopic variceal ligation; Gastroesophageal varices; Hypersplenism; Liver cirrhosis; Non-selective beta-blocker; Partial splenic embolization; Portal hypertension; Secondary prophylaxis; Thrombocytopenia.

Conflict of interest statement

Xin Sun, Anzhong Zhang, Tao Zhou, Minghui Wang, Yong Chen, Ting Zhou, Xiaoning Chen, Aiyuan Xiu, Zhi Peng, Baoquan Cheng, Xiaofeng Liu, Yanjing Gao declare that there is no conflict of interest.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of the study. PSE Partial splenic embolization
Fig.2
Fig.2
Kaplan–Meier curves of variceal rebleeding (a), variceal recurrence (b). The log-rank p values of which were 0.000 and 0.008, respectively; PSE partial splenic embolization
Fig.3
Fig.3
Follow-up results of peripheral blood cell count. a White blood cell (WBC), b red blood cell (RBC), c platelet (PLT), d hemoglobin (HGB) in EP group and E group. PSE partial splenic embolization. *There was a significant difference between the EP group and E group (p < 0.05). **It was significantly increased at this point than the pre-EP treatment (p < 0.05). ***It was significantly increased/decreased at this point than the pre-E therapy(p < 0.05)
Fig.4
Fig.4
Follow-up results of albumin concentration. PSE, partial splenic embolization. *There was a significant difference between the EP group and E group(p < 0.05). **It was significantly increased at this point than the pre-EP treatment (p < 0.05). ***It was significantly increased at this point than the pre-E therapy (p < 0.05)
Fig.5
Fig.5
Follow-up results of coagulation function parameters. a prothrombin time (PT), b international normalized ratio (INR), c prothrombin activity (PTA) in EP group and E group. PSE partial splenic embolization. *There was a significant difference between the EP group and E group (p < 0.05). **It was significantly increased/decreased at this point than the pre-EP treatment (p < 0.05)

References

    1. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38. 10.1002/hep.21907.
    1. Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Int. 2017;37(Suppl 1):104–115. doi: 10.1111/liv.13277.
    1. Puente A, Hernández-Gea V, Graupera I, Roque M, Colomo A, Poca M, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int. 2014;34:823–833. doi: 10.1111/liv.12452.
    1. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet (Lond Engl) 2003;361:952–954. doi: 10.1016/s0140-6736(03)12778-x.
    1. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752. doi: 10.1016/j.jhep.2015.05.022.
    1. Chen J, Zeng XQ, Ma LL, Huang XQ, Tseng YJ, Wang J, et al. Long-term efficacy of endoscopic ligation plus cyanoacrylate injection with or without sclerotherapy for variceal bleeding. J Dig Dis. 2016;17:252–259. doi: 10.1111/1751-2980.12331.
    1. Li L, Duan M, Chen W, Jiang A, Li X, Yang J, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med. 2017;15:111. doi: 10.1186/s12967-017-1214-8.
    1. Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut. 2003;52:1200–1205. doi: 10.1136/gut.52.8.1200.
    1. N'Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, et al. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol. 2005;17:179–184. doi: 10.1097/00042737-200502000-00008.
    1. Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 1993;18:309–314. doi: 10.1002/hep.1840180214.
    1. Lee CM, Leung TK, Wang HJ, Lee WH, Shen LK, Liu JD, et al. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia. World J Gastroenterol. 2007;13:619–622. doi: 10.3748/wjg.v13.i4.619.
    1. Tajiri T, Yoshida H, Obara K, Onji M, Kage M, Kitano S, et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Digest Endosc. 2010;22:1–9. 10.1111/j.1443-1661.2009.00929.x.
    1. Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet. 2003;361:952–954. doi: 10.1016/S0140-6736(03)12778-X.
    1. Lo G-H. Endoscopic treatments for portal hypertension. Hepatol Int. 2018;12:91–101. doi: 10.1007/s12072-017-9828-8.
    1. Huang HC, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, et al. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med. 2012;16:1125–1133. doi: 10.1111/j.1582-4934.2011.01399.x.
    1. Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281–291. doi: 10.1016/j.cld.2013.12.001.
    1. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778–793. doi: 10.1111/liv.13317.
    1. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Takesue M, Yoshida K, et al. Improved prognosis of cirrhosis patients with esophageal varices and thrombocytopenia treated by endoscopic variceal ligation plus partial splenic embolization. Dig Dis Sci. 2006;51:352–358. doi: 10.1007/s10620-006-3137-8.
    1. Duan X, Zhang K, Han X, Ren J, Xu M, Huang G, et al. Comparison of percutaneous transhepatic variceal embolization (PTVE) followed by partial splenic embolization versus PTVE alone for the treatment of acute esophagogastric variceal massive hemorrhage. J Vasc Interven Radiol: JVIR. 2014;25:1858–1865. doi: 10.1016/j.jvir.2014.08.019.
    1. Wan YM, Li YH, Xu ZY, Wu HM, Wu XN, Xu Y. Comparison of TIPS alone and combined with partial splenic embolization (PSE) for the management of variceal bleeding. Eur Radiol. 2019;29:5032–5041. doi: 10.1007/s00330-019-06046-6.
    1. Helaly AZ, Al-Warraky MS, El-Azab GI, Kohla MA, Abdelaal EE. Portal and splanchnic hemodynamics after partial splenic embolization in cirrhotic patients with hypersplenism. APMIS. 2015;123:1032–1039. doi: 10.1111/apm.12470.
    1. Hadduck TA, McWilliams JP. Partial splenic artery embolization in cirrhotic patients. World J Radiol. 2014;6:160–168. doi: 10.4329/wjr.v6.i5.160.
    1. Cai M, Huang W, Lin C, Li Z, Qian J, Huang M, et al. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications. Eur Radiol. 2016;26:370–380. doi: 10.1007/s00330-015-3839-4.
    1. Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, et al. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig Liver Dis. 2009;41:411–416. doi: 10.1016/j.dld.2008.10.005.
    1. Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 2002;49:1445–1448.
    1. Lu YF, Li XQ, Han XY, Gong XG, Chang SW. Peripheral blood cell variations in cirrhotic portal hypertension patients with hypersplenism. Asian Pacific J Trop Med. 2013;6:663–666. doi: 10.1016/s1995-7645(13)60115-7.
    1. Matsukiyo Y, Nagai H, Matsui T, Igarashi Y. Host immunological effects of partial splenic embolization in patients with liver cirrhosis. J Immunol Res. 2018;15(2018):1746391. doi: 10.1155/2018/1746391.
    1. Hidaka H, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res. 2002;23:265- 10.1016/s1386-6346(02)00002-5.
    1. Christensen BE. Quantitative determination of splenic red blood cell destruction in patients with splenomegaly. Scand J Haematol. 1975;14:295–302. doi: 10.1111/j.1600-0609.1975.tb02430.x.
    1. Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Intervent Radiol : JVIR. 2007;18:463–481. doi: 10.1016/j.jvir.2006.12.734.
    1. Hayashi H, Beppu T, Masuda T, Okabe H, Imai K, Hashimoto D, et al. Large splenic volume may be a useful predictor for partial splenic embolization-induced liver functional improvement in cirrhotic patients. J Hepato Bili Pancreat Sci. 2014;21:51–57. doi: 10.1002/jhbp.1.
    1. Mukaiya M, Hirata K, Yamashiro K, Katsuramaki T, Kimura H, Denno R. Changes in portal hemodynamics and hepatic function after partial splenic embolization (PSE) and percutaneous transhepatic obliteration (PTO) Cancer Chemother Pharmacol. 1994;33(Suppl):S37–41. doi: 10.1007/bf00686666.
    1. Ishikawa T, Kubota T, Horigome R, Kimura N, Honda H, Iwanaga A, et al. Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatology Res. 2014;44:1056–1061. doi: 10.1111/hepr.12222.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться